Fungal infections represent an increasingly significant cause of morbidity and mortality worldwide, particularly among immunocompromised individuals and hospitalized patients. Recent global estimates suggest that invasive fungal diseases affect millions of individuals annually, with high mortality rates associated with systemic infections [1-7].
Pathogenic fungi such as Candida albicans, Aspergillus fumigatus, and Cryptococcus neoformans are responsible for the majority of life-threatening fungal infections in humans [9,10,15,39]. These organisms exploit host metabolic resources while deploying specialized biochemical pathways that enable survival within the host environment [5,28].
One of the major challenges in antifungal drug development arises from the eukaryotic nature of fungal cells, which share many structural and metabolic similarities with human cells [6,8]. Consequently, only a limited number of antifungal drug classes are currently available, and many exhibit significant toxicity or reduced efficacy due to emerging resistance [11-15,35].
An important strategy for identifying selective antifungal targets involves studying inter-kingdom metabolic disparities, defined as biochemical pathways that exist in fungi but are absent or substantially different in human cells [20-24]. Examples include fungal cell-wall biosynthesis, ergosterol metabolism, siderophore-mediated iron acquisition, and the synthesis of unique secondary metabolites [16-19,25].
Understanding these pathways not only supports antifungal drug discovery but also provides opportunities for the development of laboratory-based susceptibility markers that can improve the diagnosis and monitoring of fungal infections [26,30-35].
1.1 Objectives
1.1.1 Primary Objective
To analyzemetabolic differences between humans and pathogenic fungi in order to identify fungal-specific metabolites that can serve as selective antifungal drug targets and laboratory susceptibility markers.
1.1.2 Specific Objectives
2. Methods
2.1 Study Design
This investigation was conducted as a structured metabolic pathway analysis integrating data from microbiology, fungal biochemistry, and antifungal pharmacology literature [8,18,40].
Selection of Fungal Species
Common clinically relevant fungal pathogens were analysed:
These organisms represent major etiological agents of invasive fungal infections [10,15,39].
Metabolic Pathway Analysis
Key fungal metabolic pathways were evaluated:
Laboratory Correlation
Metabolites from these pathways were correlated with available laboratory susceptibility tests, including:
3.1 Fungal-Specific Metabolic Pathways
Several metabolic pathways were found to be unique or significantly divergent in fungi compared with humans [8,18]
Table 1. Major Metabolic Differences Between Humans and Fungi
|
Metabolic Feature |
Humans |
Fungi |
Clinical Significance |
References |
|
Membrane sterol |
Cholesterol |
Ergosterol |
Target of azole and polyene drugs |
[11,18,19] |
|
Cell wall |
Absent |
Present |
Target for echinocandins |
[9,25] |
|
Iron acquisition |
Transferrin dependent |
Siderophore mediated |
Potential antifungal target |
[14] |
|
Polysaccharide synthesis |
Limited |
Extensive |
Important for virulence |
[15,25] |
|
Secondary metabolites |
Minimal |
Diverse toxins and pigments |
Diagnostic biomarkers |
[28,40] |
3.2 Ergosterol Biosynthesis as a Drug Target
The fungal cell membrane contains ergosterol, whereas human cells contain cholesterol. Inhibition of ergosterol synthesis disrupts membrane integrity [18,19,20].
Table 2. Key Enzymes in Ergosterol Biosynthesis
|
Enzyme |
Function |
Targeted Drug Class |
References |
|
Squalene epoxidase |
Sterol precursor synthesis |
Allylamines |
[11,18,20] |
|
Lanosterol demethylase |
Ergosterol formation |
Azoles |
[11,18,19] |
|
Erg3 enzyme |
Sterol modification |
Experimental inhibitors |
[18,19] |
|
Erg11 enzyme |
Demethylation step |
Azole antifungals |
[18,19,13] |
3.3 Cell Wall Metabolites
The fungal cell membrane contains ergosterol, whereas human cells contain cholesterol. Inhibition of ergosterol synthesis disrupts membrane integrity and fungal growth [18,19,20]
Table 3. Major Fungal Cell Wall Components
|
Component |
Function |
Diagnostic / Therapeutic Relevance |
References |
|
β-1,3-glucan |
Structural support |
Serum biomarker |
[9,22,25] |
|
Chitin |
Mechanical strength |
Target for chitin synthase inhibitors |
[25] |
|
Mannoproteins |
Adhesion |
Immune recognition |
[17,27] |
|
α-glucans |
Virulence factor |
Potential drug target |
[15,28] |
3.4 Iron Acquisition via Siderophores
Fungi produce specialized molecules known as siderophores that scavenge iron from the host environment [14].
Table 4. Common Fungal Siderophores
|
Siderophore |
Producing Fungi |
Biological Role |
References |
|
Ferricrocin |
Aspergillus species |
Iron storage |
[14,15] |
|
Triacetylfusarinine C |
Aspergillus species |
Iron transport |
[14] |
|
Rhizoferrin |
Mucorales |
Iron uptake |
[14,40] |
|
Coprogen |
Various fungi |
Iron scavenging |
[14] |
3.5 Secondary Metabolites
Fungal pathogens produce various secondary metabolites involved in virulence and host interaction [28].
Table 5. Important Fungal Secondary Metabolites
|
Metabolite |
Fungal Source |
Clinical Importance |
References |
|
Gliotoxin |
Aspergillus fumigatus |
Immunosuppression |
[15,28] |
|
Melanin |
Cryptococcus neoformans |
Protection from host immunity |
[5,28] |
|
Candidalysin |
Candida albicans |
Tissue damage |
[28,34] |
|
Fumagillin |
Aspergillus species |
Angiogenesis inhibition |
[15,40] |
3.6 Laboratory Susceptibility Markers
Several metabolites may serve as measurable markers for antifungal susceptibility [22,38].
Table 6. Potential Metabolic Susceptibility Markers
|
Marker |
Detection Method |
Clinical Utility |
References |
|
β-D-glucan |
Serum assay |
Diagnosis of invasive fungal infection |
[22,38] |
|
Ergosterol levels |
Chromatography |
Drug response monitoring |
[18,20] |
|
Siderophore production |
Mass spectrometry |
Virulence indicator |
[14] |
|
Chitin fragments |
Enzyme assay |
Fungal growth marker |
[25] |
This analysis demonstrates that inter-kingdom metabolic disparities provide valuable insight into antifungal drug development. Fungal-specific biochemical pathways offer opportunities for selective targeting while minimizing toxicity to human cells.
The ergosterol pathway remains one of the most successful antifungal targets, exploited by azoles and polyenes. However, emerging resistance in pathogens such as Candida auris has highlighted the need for additional targets.[7]
Cell-wall biosynthesis represents another promising area. Agents targeting β-glucan synthesis have already shown success, but further exploration of chitin metabolism may expand therapeutic options.[8]
Iron acquisition mechanisms, particularly siderophore production in fungi like Aspergillus fumigatus, are emerging as potential antifungal targets and diagnostic markers.[9]
Integration of metabolic biomarkers into laboratory diagnostics may also improve antifungal susceptibility testing. Metabolite-based assays could provide rapid indicators of fungal growth and drug response compared with traditional culture methods.
Metabolic disparities between humans and fungi provide a powerful framework for antifungal drug discovery and laboratory diagnostics. Unique fungal metabolites such as ergosterol intermediates, β-glucans, siderophores, and virulence-associated secondary metabolites represent promising targets for selective therapy and susceptibility monitoring. Future research integrating metabolomics, molecular diagnostics, and antifungal pharmacology may significantly improve management of invasive fungal infections.
Future Perspectives
Future research should focus on integrating metabolomics, genomics, and molecular diagnostics to better understand fungal metabolic networks and their role in pathogenicity. Advances in high-throughput metabolite profiling and mass spectrometry-based diagnostics may allow rapid detection of fungal biomarkers in clinical samples. Additionally, exploring novel metabolic enzymes and pathways unique to fungi could facilitate the development of next-generation antifungal drugs with improved selectivity and reduced toxicity. The incorporation of metabolic biomarkers into routine laboratory susceptibility testing may also enable faster therapeutic decision-making and strengthen antifungal stewardship programs. Continued investigation of fungal metabolic diversity will therefore be essential for improving the diagnosis, treatment, and prevention of invasive fungal diseases.
[1] Gordon D. Brown, David W. Denning, Neil A. R. Gow, Stuart M. Levitz, Mihai G. Netea, Theodore C. White. Hidden killers: human fungal infections. Science Translational Medicine. 2012;4(165):165rv13.
[2] Friday Bongomin, Samuel Gago, Rita O. Oladele, David W. Denning. Global and multi-national prevalence of fungal diseases—estimate precision. Journal of Fungi. 2017;3(4):57.
[3] Matthew C. Fisher, Nicholas J. Hawkins, Dominique Sanglard, Sarah J. Gurr. Worldwide emergence of resistance to antifungal drugs challenges human health and food security. Science. 2018;360(6390):739-742.
[4] David W. Denning, Michael J. Bromley. Infectious disease: how to bolster the antifungal pipeline. Science. 2015;347(6229):1414-1416.
[5] Arturo Casadevall, Claudia Coelho, Radames J. B. Cordero, QianruDragotakes, Eun Jung, Rahul Vij, Michelle P. Wear. The capsule of Cryptococcus neoformans. Virulence. 2019;10(1):822-831.
[6] Bart Jan Kullberg, MaikenCavlingArendrup. Invasive candidiasis. New England Journal of Medicine. 2015;373(15):1445-1456.
[7] David W. Denning. Global incidence and mortality of severe fungal disease. Lancet Infectious Diseases. 2024;24:e428-e438.
[8] Joseph R. Perfect. The antifungal pipeline: a reality check. Nature Reviews Drug Discovery. 2017;16(9):603-616.
[9] David S. Perlin. Echinocandin resistance in Candida. Clinical Infectious Diseases. 2015;61(S6):S612-S617.
[10] Mary Ann Pfaller, David J. Diekema. Epidemiology of invasive candidiasis. Clinical Microbiology Reviews. 2007;20(1):133-163.
[11] Frederick C. Odds, Alistair J. P. Brown, Neil A. R. Gow. Antifungal agents: mechanisms of action. Trends in Microbiology. 2003;11(6):272-279.
[12] Paul E. Verweij, Erik Snelders, Gerrit H. J. Kema, Emilio Mellado, Willem J. G. Melchers. Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use? Lancet Infectious Diseases. 2009;9(12):789-795.
[13] Emilio Mellado, Willem J. G. Melchers, Paul E. Verweij. Azole resistance in Aspergillus fumigatus: mechanisms and clinical implications. Future Microbiology. 2011;6(3):335-347.
[14] Howard Haas. Iron acquisition in fungal pathogens. Nature Reviews Microbiology. 2014;12(9):659-671.
[15] Jean-Paul Latgé, George Chamilos.Aspergillus fumigatus and aspergillosis. Clinical Microbiology Reviews. 2019;33(1):e00140-18.
[16] Leah E. Cowen, Dominique Sanglard, Stuart J. Howard, Paul D. Rogers, David S. Perlin. Mechanisms of antifungal drug resistance. Cold Spring Harbor Perspectives in Medicine. 2015;5(7):a019752.
[17] Ramon A. Drummond, Chad Steele. Recent advances in antifungal immunity. Current Opinion in Microbiology.2018;40:1-6.
[18] Lingyun Song, Sha Wang, Hang Zou, Xiaokang Yi, Shihan Jia, Rongpeng Li, Jinxing Song. Regulation of ergosterol biosynthesis in pathogenic fungi: opportunities for therapeutic development. Microorganisms. 2025;13(4):862.
[19] Daniel Eliaš, Nora TóthHervay, YvettaGbelská. Ergosterol biosynthesis and regulation impact antifungal resistance and virulence of Candida species. Stresses. 2024;4(4):641-662.
[20] Sanjay B. Rajput, Suresh M. Karuppayil. Small molecules inhibit growth, viability and ergosterol biosynthesis in Candida albicans. SpringerPlus.2013;2:26.
[21] Michael Hoenigl, Daniel Seidel, Rolf Sprute, Cristiano Cunha, Maurizio Oliverio, Gustavo H. Goldman. COVID-19 associated fungal infections. Nature Microbiology. 2022;7(8):1127-1140.
[22] Zachary Freeman Weiss, Ana Leon, Sara Koo. The evolving landscape of fungal diagnostics. Journal of Fungi. 2021;7(2):127.
[23] Manuel Bassetti, Daniele Roberto Giacobbe, Carina Agvald-Ohman. Invasive fungal diseases in adult ICU patients: consensus definitions. Intensive Care Medicine.2024;50:502-515.
[24] William E. Dismukes, Peter G. Pappas, Jack D. Sobel. Clinical Mycology. Oxford University Press; 2003.
[25] Carol A. Munro, Neil A. R. Gow. Chitin synthesis in human pathogenic fungi. Medical Mycology. 2001;39(1):41-53.
[26] Leah E. Cowen. The evolution of fungal drug resistance. Annual Review of Microbiology.2008;62:309-338.
[27] Judith Berman, Tamar Sudbery.Candida albicans: a molecular revolution built on lessons from budding yeast. Nature Reviews Genetics. 2002;3(12):918-930.
[28] Anand S. Jhingran, George S. Deepe. Fungal virulence factors and host immunity. Cell Host & Microbe. 2016;19(5):627-637.
[29] Gordon D. Brown, Mihai G. Netea. Exciting developments in the immunology of fungal infections. Cell Host & Microbe. 2012;11(5):422-424.
[30] Ronan C. O’Meara, Leah E. Cowen. Hsp90-dependent regulation of antifungal drug resistance. Current Opinion in Microbiology.2014;20:11-17.
[31] David W. Denning. Invasive aspergillosis. Clinical Infectious Diseases. 1998;26(4):781-805.
[32] Paul E. Verweij, David W. Denning. The challenge of invasive fungal infections. Lancet.1997;349:119-123.
[33] Kerry A. Marr, Paul D. Schlamm, Dimitrios P. Kontoyiannis. Combination antifungal therapy for invasive aspergillosis. Clinical Infectious Diseases.2004;39:797-802.
[34] Richard A. Calderone, William A. Fonzi. Virulence factors of Candida albicans. Trends in Microbiology. 2001;9(7):327-335.
[35] Daniel P. Kontoyiannis, Russell E. Lewis. Antifungal drug resistance of pathogenic fungi. Lancet.2002;359:1135-1144.
[36] Matthew C. Fisher, Timothy R. Henk, Conrad J. Briggs. Emerging fungal threats to human health. Nature.2012;484:186-194.
[37] Antonio Cassone, Antonio Casadevall. Recent progress in vaccines against fungal diseases. Current Opinion in Microbiology. 2012;15(4):427-433.
[38] David S. Perlin, John E. Wiederhold. Culture-independent molecular diagnostics for fungal infections. Clinical Microbiology Reviews. 2017;30(2):529-560.
[39] Anuradha Chowdhary, Jacques F. Meis, Cornelia Lass-Flörl.Candida auris: a rapidly emerging cause of hospital-acquired infections. Clinical Microbiology Reviews. 2017;30(2):529-563.
[40] Joseph Heitman, Christina A. Cuomo, David A. Carter, Jennifer A. Perfect. The Fungal Kingdom. ASM Press; 2017.
IJBMR -ISSN: 0976:6685. ©Copyright 2026 This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Published by BioMedSciDirect Publications